CATX Stock Overview Develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Perspective Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Perspective Therapeutics Historical stock prices Current Share Price US$2.85 52 Week High US$19.05 52 Week Low US$2.70 Beta 1.14 1 Month Change -17.87% 3 Month Change -76.70% 1 Year Change -25.00% 3 Year Change -29.80% 5 Year Change -53.44% Change since IPO -71.50%
Recent News & Updates
Independent Director recently bought US$100k worth of stock Dec 08
CEO & Director recently bought US$100k worth of stock Nov 27
New major risk - Revenue and earnings growth Nov 25
Price target decreased by 15% to US$18.17 Nov 24
Perspective Therapeutics, Inc. Announces Initial Results from its Ongoing Phase 1/2a Clinical Trial of [212Pb] VMT-a-Net Nov 21
New minor risk - Share price stability Nov 18 See more updates
Independent Director recently bought US$100k worth of stock Dec 08
CEO & Director recently bought US$100k worth of stock Nov 27
New major risk - Revenue and earnings growth Nov 25
Price target decreased by 15% to US$18.17 Nov 24
Perspective Therapeutics, Inc. Announces Initial Results from its Ongoing Phase 1/2a Clinical Trial of [212Pb] VMT-a-Net Nov 21
New minor risk - Share price stability Nov 18
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 14
New major risk - Revenue size Nov 13
Perspective Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 31
Perspective Therapeutics Begins Shipping Investigational Products from Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey Oct 16
Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy (212Pb)Vmt01 Based on Data Presented At the 21St International Congress of the Society for Melanoma Research Oct 11
Perspective Therapeutics Grants Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma Sep 05
Consensus revenue estimates increase by 51%, EPS downgraded Aug 20 Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $49.868808 million.
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 13
Perspective Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Jul 22
CFO & Co-Principal Financial Officer recently bought US$177k worth of stock Jun 19
CEO & Director recently bought US$117k worth of stock Jun 14 Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.998535 million. May 25
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 17 Perspective Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024
New minor risk - Profitability Apr 09
No longer forecast to breakeven Apr 09
Full year 2023 earnings released: US$0.14 loss per share (vs US$0.10 loss in FY 2022) Mar 28
Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024 Mar 26 Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc. Mar 07
Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors Mar 06
Perspective Therapeutics, Inc. (NYSEAM:CATX) completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.
Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform Feb 02
Chief Medical Officer recently bought US$140k worth of stock Jan 28
Forecast to breakeven in 2026 Jan 26
Perspective Therapeutics, Inc. announced that it has received $20.846671 million in funding from Lantheus Alpha Therapy, LLC Jan 23 Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in funding Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering.
Chief Medical Officer recently bought US$189k worth of stock Dec 20
Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine Tumors Dec 07 Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in Germany
Perspective Therapeutics, Inc. Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals Nov 28
New major risk - Financial position Nov 20
Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Nov 19 Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Nov 18
Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint Nov 17
Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2A Study of [(212)Pb VMT-a-Net for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors Nov 09
Perspective Therapeutics, Inc. Announces Two Upcoming Investigator-Initiated Trials Oct 11
Perspective Therapeutics, Inc. Announces Presentation of Positive Early Clinical Data for VMT-a-NET at 36th Annual Congress of European Association of Nuclear Medicine Sep 13
Perspective Therapeutics, Inc. Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine Sep 12
Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023 Aug 24
New major risk - Financial position Aug 14 Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma
Second quarter 2023 earnings released Aug 12 Perspective Therapeutics, Inc. Announces Termination of Jennifer Streeter as Chief Operating Officer Jul 15
Less than half of directors are independent Jul 14
Perspective Therapeutics, Inc.'s Cesium-131 Features at the American Brachytherapy Society's Annual Conference Jun 28
Perspective Therapeutics, Inc. Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates Jun 22
Less than half of directors are independent Jun 03
Perspective Therapeutics, Inc. Announces Changes to the Board of Directors May 18
First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.009 loss in 1Q 2022) May 16
Chairperson of the Board exercised options to buy US$129k worth of stock. Apr 21
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Feb 18
Isoray, Inc. Announces Termination of William Cavanagh III as Chief Research and Development Officer Feb 12
Isoray, Inc. Announces Executive Changes Feb 07 Shareholder Returns CATX US Biotechs US Market 7D -18.1% -3.6% -2.4% 1Y -25.0% -2.6% 23.4%
See full shareholder returns
Return vs Industry: CATX underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: CATX underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is CATX's price volatile compared to industry and market? CATX volatility CATX Average Weekly Movement 18.6% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: CATX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CATX's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans.
Show more Perspective Therapeutics, Inc. Fundamentals Summary How do Perspective Therapeutics's earnings and revenue compare to its market cap? CATX fundamental statistics Market cap US$192.62m Earnings (TTM ) -US$57.71m Revenue (TTM ) US$1.56m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CATX income statement (TTM ) Revenue US$1.56m Cost of Revenue US$0 Gross Profit US$1.56m Other Expenses US$59.27m Earnings -US$57.71m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.85 Gross Margin 100.00% Net Profit Margin -3,706.62% Debt/Equity Ratio 0.5%
How did CATX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 03:20 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Perspective Therapeutics, Inc. is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Edward Woo Ascendiant Capital Markets LLC Alec Stranahan BofA Global Research Yuan Zhi B. Riley Securities, Inc.
Show 11 more analysts 
